Elizabeth Mora Named Inogen Board Chair

Inogen Inc. has welcomed a new board chairperson.

The company recently named Elizabeth (Beth) Mora to succeed Heath Lukatch, Ph.D., who has led the governing body since 2008. Lukatch will remain on the board as a director and member of the Compensation Committee. 

“It has been an honor to serve as chairperson of Inogen’s Board of Directors and I am confident Beth is the right choice to assume the chairperson position, as evidenced by the tremendous support she has received from her fellow directors,” said Lukatch. “As we continue to evolve Inogen, including recent changes we have made to our executive team, these alterations to the Board are consistent with our goal of transforming Inogen into a more prominent player in respiratory care. Beth’s leadership and operational experience at world-leading research institutions, combined with her track record on public company boards, including serving as a chair of several audit committees, will be instrumental in leading the board and continuing Inogen’s growth. I look forward to continuing to work with her, other directors and the management team, as we continue on our path to transform Inogen.”

Mora has served as a board member since May 24, 2021, and is also a member of the Audit and Compliance Committees.  
 
In addition to its change of leadership, Inogen’s board is losing Ray Huggenberger, who has been a member since 2008. He is retiring from the board and transitioning to an advisory role. Mora replaces Huggenberger as chair of the Compliance Committee. Following Huggenberger’s retirement, the board has been reduced to seven members. “It has been an honor and a privilege to have the opportunity to work with so many talented colleagues at Inogen over the years. I am confident the company is well-positioned for future success,” Hugenberger said.
 
“I want to thank Ray for his years of dedication to Inogen. In his prior roles as president and CEO as well as a director, Ray has made significant contributions to the company and we have benefitted immensely from his leadership, counsel and expertise. We wish him all the best,” Lukatch said. 

In connection with these board changes, Inogen director Kristen Miranda, has reclassified and become a Class III director, joining with Lukatch. Class I directors are comprised of Heather Rider and Mora, and Class II directors are comprised of Loren McFarland, Benjamin Anderson-Ray, and Nabil Shabshab.
 
“Over the past seven months, I have worked closely with Beth and valued her partnership and counsel.” said Shabshab, president and CEO of Inogen. “I am very excited about continuing our thought partnership and collaboration to build a stronger Inogen.”
 
“I am honored to take on this new role as chair of Inogen’s Board of Directors at such an important time in the company’s evolution,” Mora said. “I look forward to continuing to work alongside Nabil, Heath, and the rest of the board and leadership team, as we continue to build on our strategic goals of increasing POC market penetration and improving patient access, all while delivering sustainable, long-term value for stockholders.”
 
Inogen is a medical technology company offering respiratory products for use in the homecare setting. The company primarily develops, manufactures, and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.